Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
10:11am, Friday, 12'th Sep 2025
Black Diamond sharpens focus on silevertinib after outlicensing BDTX-4933, cutting costs, and securing cash runway into late 2027.
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
12:06pm, Friday, 05'th Sep 2025
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX?
11:51am, Thursday, 04'th Sep 2025
Black Diamond focuses on silevertinib for NSCLC and GBM, with key trial readouts due in late 2025 and FDA feedback expected in 2026.
Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash
11:13am, Monday, 25'th Aug 2025
Black Diamond Therapeutics' Silvertinib (BDTX-1535) targets non-classical EGFR mutations in NSCLC, addressing an unmet need left by current standard Osimertinib. Preliminary Phase 2 results for Silver
Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why
01:01pm, Tuesday, 19'th Aug 2025
Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?
10:41am, Monday, 18'th Aug 2025
Here is how Black Diamond (BDTX) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
07:30am, Thursday, 07'th Aug 2025
CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside
06:38am, Tuesday, 10'th Jun 2025
Black Diamond Therapeutics's novel EGFR inhibitor shows promise in addressing resistance mutations in NSCLC and glioblastoma, with key phase 2 data expected in Q4 2025. The Servier licensing deal stre
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
08:00am, Thursday, 29'th May 2025
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
04:05pm, Monday, 12'th May 2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic m
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Monday, 31'st Mar 2025
CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier
12:58am, Tuesday, 25'th Mar 2025
Black Diamond Therapeutics' strategic deal with Servier makes BDTX undervalued, with a $70M upfront payment and potential $710M in milestone payments and royalties. BDTX is trading below its net cash
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
07:00am, Wednesday, 19'th Mar 2025
SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics: In Decline, But Why?
03:47pm, Thursday, 13'th Mar 2025
Black Diamond Therapeutics, Inc. shows promising developments in its pipeline updates, highlighting significant advancements in targeted cancer therapies. The financial overview reveals a stable cash
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
04:01pm, Thursday, 06'th Mar 2025
CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
